Keyword :   first line therapy

Advantages and risks of using CDK4/6 inhibitors, including palbociclib, in first-line therapy for HR+ metastatic breast cancer
Т. 14, №4 (56)
Prospects for the use of pembrolizumab in the treatment of previously untreated patients with advanced malignant pleural mesothelioma
Author:Nemish I.L. Т. 13, № 3 (51)